Piper Sandler upgraded shares of Proteostasis Therapeutics (NASDAQ:PTI) from a neutral rating to an overweight rating in a research report report published on Wednesday morning, The Fly reports.
PTI has been the topic of a number of other research reports. Zacks Investment Research raised Proteostasis Therapeutics from a hold rating to a buy rating and set a $1.50 price objective on the stock in a report on Wednesday, August 12th. ValuEngine lowered Proteostasis Therapeutics from a buy rating to a hold rating in a report on Thursday, July 2nd. Finally, HC Wainwright reissued a buy rating on shares of Proteostasis Therapeutics in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $4.54.
Shares of NASDAQ PTI opened at $1.23 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.69 and a current ratio of 6.69. The firm has a market cap of $64.18 million, a price-to-earnings ratio of -1.46 and a beta of 1.06. The business’s 50-day simple moving average is $1.22 and its 200-day simple moving average is $1.37. Proteostasis Therapeutics has a 52 week low of $0.70 and a 52 week high of $4.72.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.04. As a group, equities research analysts forecast that Proteostasis Therapeutics will post -0.73 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP raised its stake in Proteostasis Therapeutics by 11.3% during the 1st quarter. Two Sigma Advisers LP now owns 168,900 shares of the company’s stock valued at $193,000 after purchasing an additional 17,200 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Proteostasis Therapeutics in the 2nd quarter valued at $50,000. Virtu Financial LLC acquired a new position in shares of Proteostasis Therapeutics in the 2nd quarter valued at $48,000. WINTON GROUP Ltd raised its stake in shares of Proteostasis Therapeutics by 21.3% in the 2nd quarter. WINTON GROUP Ltd now owns 824,750 shares of the company’s stock valued at $1,130,000 after buying an additional 144,631 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in shares of Proteostasis Therapeutics by 47.1% in the 2nd quarter. Blair William & Co. IL now owns 30,055 shares of the company’s stock valued at $41,000 after buying an additional 9,630 shares in the last quarter. Hedge funds and other institutional investors own 16.64% of the company’s stock.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.